• 1
    American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007.
  • 2
    Ries LAG,Melbert D,Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007. Available at:, based on November 2006 SEER data submission. Accessed March 30, 2007.
  • 3
    Cleator S,Parton M,Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer. 2002; 9: 183195.
  • 4
    Haffty BG,Yang Q,Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 56525657.
  • 5
    Breen N,Wesley MN,Merrill RM,Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis. 1999; 9: 111125.
  • 6
    Chu KC,Lamar CA,Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 28532860.
  • 7
    Clegg LX,Li FP,Hankey BF,Chu K,Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study [see comment]. Arch Intern Med. 2002; 162: 19851993.
  • 8
    Eley JW,Hill HA,Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994; 272: 947954.
  • 9
    Dayal HH,Power RN,Chiu C. Race and socio-economic status in survival from breast cancer. J Chronic Dis. 1982; 35: 675683.
  • 10
    Furberg H,Millikan R,Dressler L,Newman B,Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat. 2001; 68: 3343.
  • 11
    Amend K,Hicks D,Ambrosone C. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 2006; 66: 83278330.
  • 12
    Porter PL,Lund MJ,Lin MG, et al. Racial differences in expression of cell cycle regulatory proteins in breast cancer: study of young African American and white women in Atlanta. Cancer. 2004; 100: 25332542.
  • 13
    Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002; 73: 4559.
  • 14
    Joslyn SA. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer. 2002; 95: 17591766.
  • 15
    Du W,Simon MS. Racial disparities in treatment and survival of women with stage I-III breast cancer at a large academic medical center in metropolitan Detroit. Breast Cancer Res Treat. 2005; 91: 243248.
  • 16
    Lund MJ,Brawley OW,Ward KC,Young JL,Gabram SGA,Eley JW. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2007 21 July [Epub ahead of print].
  • 17
    Lund MJ,Eley JW,Brawley OW,Liff JM,Coates RJ,Porter PL. Racial differences in triple negative breast tumors among women in Atlanta. Oral presentation of abstract at: American Association of Cancer Researchers Annual Meeting, Washington, DC, April 15, 2006. Abstract LB-4.
  • 18
    Carey LA,Perou CM,Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 24922502.
  • 19
    Sorlie T,Tibshirani R,Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 84188423.
  • 20
    Sorlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 1086910874.
  • 21
    Demicheli R,Retsky JW,Hrushesky WJ,Baum M,Gukas ID,Jatoi I. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer. 2007; 110: 18801888.
  • 22
    Bauer KR,Brown M,Cress RD,Parise CR,Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109: 17211728.
  • 23
    Millikan RC,Newman B,Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123139. Epub 2007 Jun 20.
  • 24
    Fritz A,Percy C,Jack A,Bloop D. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
  • 25
    Greene FL,Page DL,Fleming ID, et al., eds. AJCC Cancer Staging Manual.6th ed. New York: Springer-Verlag; 2002.
  • 26
    Carrizosa DR,Carey LA. Adjuvant systemic therapy in young women. Breast Dis. 2005; 23: 6771.
  • 27
    Whitworth A. New research suggests access, genetic differences play role in high minority cancer death rate. J Natl Cancer Inst. 2006; 98: 669.
  • 28
    Olopade OI,Ikpatt FO,Dignam JJ, et al. “Intrinsic gene expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. Presented at: American Society of Clinical Oncology Annual Meeting, New Orleans, Louisiana, June 2004.
  • 29
    Birnbaum D,Bertucci F,Ginestier C,Tagett R,Jacquemier J,Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminous? [review]. Int J Oncol. 2004; 25: 249258.
  • 30
    Tischkowitz MD,Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006; 5: 963967.
  • 31
    Yehiely F,Moyano JV,Evans JR,Nielsen TO,Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006; 12: 537544.
  • 32
    Sorlie T,Wang Y,Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across 3 different platforms. BMC Genomics. 2006; 7: 127.
  • 33
    Sotiriou C,Neo SY,McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100: 1039310398.
  • 34
    Yang XR,Sherman ME,Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 439443.
  • 35
    Perou CM,Sorlie T,Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747752.
  • 36
    National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Version 1. Fort Washington, Penn: National Comprehensive Cancer Network; 2006.
  • 37
    Romond EH,Perez EA,Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 16731684.
  • 38
    Dunnwald LK,Rossing MA,Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9: R6 .
  • 39
    Trivers KF,Gammon MD,Abrahamson PE, et al. Association between reproductive factors and breast cancer survival in younger women. Breast Cancer Res Treat. 2007; 103: 93102.